Skip to main content

Table 2 Tumor response according chemotherapy associated with trastuzumab (166 evaluable patients)1

From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

  Docetaxel + Trastuzumab N = 99 95% C.I. Vinorelbine + Trastuzumab N = 67 95% C.I. P*
ORR (CR+PR) 76 (77%) 68%-84% 38 (57%) 45%-68% 0.01
   CR 16 (16%)   10 (15%)   
   PR 60 (61%)   28 (42%)   
   SD 18 (18%)   17 (25%)   
   PD 5 (5%)   12 (18%)   
CBR (CR+PR+SD ≥ 6 months) 88 (89%) 81%-94% 51 (76%) 65%-85% 0.07
  1. Abbreviations: C.I., confidence interval: RR, response rate: CR, complete remission: PR, partial remission: SD, stable disease: PD, progressing disease: CBR, clinical benefit rate
  2. 1For 12 patients (7 receiving docetaxel and 5 receiving vinorelbine) tumor response was not available at the time of the analysis
  3. *Chi square test.